Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145–54. https://doi.org/10.1038/s41584-020-0373-9.

Article  CAS  PubMed  Google Scholar 

Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatric Rheumatology. 2018;16(1):46. https://doi.org/10.1186/s12969-018-0255-8.

Article  PubMed  PubMed Central  Google Scholar 

Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev. 2000(3):Cd000212. https://doi.org/10.1002/14651858.Cd000212.

Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–7. https://doi.org/10.1056/nejm199502023320503.

Article  CAS  PubMed  Google Scholar 

Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. https://doi.org/10.1136/ard-2022-223356.

Article  CAS  PubMed  Google Scholar 

Liu L, Liu S, Wang C, Guan W, Zhang Y, Hu W, et al. Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review. JCR. J Clin Rheumatol. 2019;25(5):197–202. https://doi.org/10.1097/rhu.0000000000000810.

Article  CAS  PubMed  Google Scholar 

Fraenkel L, Bathon JM, England BR, St.Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924–39. https://doi.org/10.1002/acr.24596.

Article  Google Scholar 

Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic athritis. Arthritis Rheumatol. 2022;74(4):553–69. https://doi.org/10.1002/art.42037.

Article  PubMed  PubMed Central  Google Scholar 

Vena GA, Cassano N, Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag. 2018;14:105–16. https://doi.org/10.2147/tcrm.S154745.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma P, Scott DG. Optimizing methotrexate treatment in rheumatoid arthritis: the case for subcutaneous methotrexate prior to biologics. Drugs. 2015;75(17):1953–6. https://doi.org/10.1007/s40265-015-0486-7.

Article  CAS  PubMed  Google Scholar 

Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012;64(9):1349–56. https://doi.org/10.1002/acr.21697.

Article  CAS  PubMed  Google Scholar 

Fráňová J, Fingerhutová Š, Kobrová K, Srp R, Němcová D, Hoza J, et al. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration. Pediatr Rheumatol Online J. 2016;14(1):36. https://doi.org/10.1186/s12969-016-0099-z.

Article  PubMed  PubMed Central  Google Scholar 

van Dijkhuizen EH, Pouw JN, Scheuern A, Hügle B, Hardt S, Ganser G, et al. Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study. Clin Exp Rheumatol. 2016;34(1):148–54.

PubMed  Google Scholar 

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2019;14(1):4–22. https://doi.org/10.1093/ecco-jcc/jjz180.

Article  Google Scholar 

Qiu Y, Mao R, Chen BL, Zhang SH, Guo J, He Y, et al. Effects of combination therapy with immunomodulators on trough levels and antibodies against tumor necrosis factor antagonists in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2017;15(9):1359–72.e6. https://doi.org/10.1016/j.cgh.2017.02.005.

Article  CAS  PubMed  Google Scholar 

van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis. 2020;15(2):171–94. https://doi.org/10.1093/ecco-jcc/jjaa161.

Article  Google Scholar 

Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2021;16(1):2–17. https://doi.org/10.1093/ecco-jcc/jjab178.

Article  Google Scholar 

Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, et al. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. 2018;155(4):1098–108.e9. https://doi.org/10.1053/j.gastro.2018.06.046.

Article  CAS  PubMed  Google Scholar 

Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55(3):340–61. https://doi.org/10.1097/MPG.0b013e3182662233.

Article  CAS  PubMed  Google Scholar 

Bujor AM, Janjua S, LaValley MP, Duran J, Braun J, Felson DT. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PLoS One. 2019;14(9):e0221823. https://doi.org/10.1371/journal.pone.0221823.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Wang F, Tang J, Li Z, Qi Y, Li G, Wang F. Oral methotrexate at doses 15-25 mg/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2022;41(9):2701–12. https://doi.org/10.1007/s10067-022-06221-z. Recent systematic review reporting no evident difference in efficacy or toxicity between oral administration of MTX versus subcutaneous administration in RA.

Article  CAS  PubMed  Google Scholar 

Heuvelmans J, den Broeder N, van den Elsen GAH, den Broeder AA, van den Bemt BJF. Effectiveness and tolerability of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis. Rheumatology (Oxford). 2021;61(1):331–6. https://doi.org/10.1093/rheumatology/keab313.

Article  CAS  PubMed  Google Scholar 

Vidal-Montal P, Thomas M, Combier A, Steelandt A, Miceli-Richard C, Molto A, et al. Comparison of subcutaneous and oral methotrexate initiation in rheumatoid arthritis in current practice. Jt Bone Spine. 2023:105620. https://doi.org/10.1016/j.jbspin.2023.105620.

Looijen AEM, van Mulligen E, van der Helm-van Mil AHM, de Jong PHP. Tapering subcutaneous methotrexate causes more disease flares compared with tapering oral administration in established rheumatoid arthritis patients. Rheumatology (Oxford). 2022;61(8):e216–e8. https://doi.org/10.1093/rheumatology/keac154.

Article  CAS  PubMed  Google Scholar 

Li CKH, Baker K, Jones T, Coulson E, Roberts A, Birrell F. Safety and tolerability of subcutaneous methotrexate in routine clinical practice. Arthritis Care Res (Hoboken). 2021;73(9):1306–11. https://doi.org/10.1002/acr.24334.

Article  CAS  PubMed  Google Scholar 

• Hebing RC, Lin M, Bulatović Ćalasan M, Muller IB, Mahmoud S, Heil S, et al. Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial. Ann Rheum Dis. 2023;82(4):460–7. https://doi.org/10.1136/ard-2022-223398. Longitudinal study which showed that MTX-PG levels are significantly higher in RBCs after subcutaneous MTX administration versus oral administration in the first few months of treatment, while in PBMCs no difference in MTX-PG accumulation was noted between both administration routes.

Article  CAS  Google Scholar 

Bulatović Ćalasan M, Heijstek MW, Verkaaik M, van Dijkhuizen EHP, Armbrust W, Hoppenreijs EPA, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011;63(7):2007–13. https://doi.org/10.1002/art.30367.

Article  CAS  Google Scholar 

Hugle B, van Dijkhuizen EHP. MTX intolerance in children and adolescents with juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(7):1482–8. https://doi.org/10.1093/rheumatology/keaa139.

Article  CAS  PubMed  Google Scholar 

Patil P, Parker RA, Rawcliffe C, Olaleye A, Moore S, Daly N, et al. Methotrexate-induced nausea and vomiting in adolescent and young adult patients. Clin Rheumatol. 2014;33(3):403–7. https://doi.org/10.1007/s10067-013-2389-x.

Article  PubMed  Google Scholar 

Bulatović Ćalasan M, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther. 2013;15(6):R217. https://doi.org/10.1186/ar4413.

Article  CAS  PubMed Central  Google Scholar 

Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004;31(1):179–82.

CAS  PubMed  Google Scholar 

Tornero Molina J, Ballina García FJ, Calvo Alén J, Caracuel Ruiz MÁ, Carbonell Abelló J, López Meseguer A, et al. Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration routes. Reumatol Clin. 2015;11(1):3–8. https://doi.org/10.1016/j.reumae.2014.02.006.

Article  PubMed  Google Scholar 

Kromann CB, Lage-Hansen PR, Koefoed M, Jemec GB. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? J Dermatolog Treat. 2015;26(2):188–90. https://doi.org/10.3109/09546634.2014.927817.

Article  CAS  PubMed  Google Scholar 

Blits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, et al. Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013;65(11):2791–802. https://doi.org/10.1002/art.38094.

Article  CAS  PubMed